Header cover image

Market Cap


Last Updated

2021/04/11 09:17 UTC

Data Sources

Company Financials

Executive Summary

Yipinhong Pharmaceutical Co.,Ltd, together with its subsidiaries, engages in the research and development, production, and sale of pharmaceutical products. More Details

Snowflake Analysis

Flawless balance sheet with proven track record.

Share Price & News

How has Yipinhong PharmaceuticalLtd's share price performed over time and what events caused price changes?

Latest Share Price and Events

Stable Share Price: 300723 is not significantly more volatile than the rest of CN stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: 300723's weekly volatility (6%) has been stable over the past year.

Market Performance

7 Day Return




CN Pharmaceuticals


CN Market

1 Year Return




CN Pharmaceuticals


CN Market

Return vs Industry: 300723 underperformed the CN Pharmaceuticals industry which returned 15.8% over the past year.

Return vs Market: 300723 underperformed the CN Market which returned 28.4% over the past year.

Shareholder returns

7 Day-0.1%-0.1%-1.1%
30 Day-3.4%3.9%1.0%
90 Day21.6%-5.4%-5.8%
1 Year11.0%10.5%16.9%15.8%30.4%28.4%
3 Year10.0%8.6%25.2%20.7%25.9%19.9%
5 Yearn/a41.6%34.1%23.6%15.5%

Long-Term Price Volatility Vs. Market

How volatile is Yipinhong PharmaceuticalLtd's share price compared to the market and industry in the last 5 years?

Simply Wall St News

No news available


Is Yipinhong PharmaceuticalLtd undervalued compared to its fair value and its price relative to the market?


Price to Earnings (PE) ratio

Share Price vs. Fair Value

Below Fair Value: 300723 (CN¥47.73) is trading above our estimate of fair value (CN¥4.99)

Significantly Below Fair Value: 300723 is trading above our estimate of fair value.

Price To Earnings Ratio

PE vs Industry: 300723 is poor value based on its PE Ratio (33.4x) compared to the CN Pharmaceuticals industry average (31.2x).

PE vs Market: 300723 is good value based on its PE Ratio (33.4x) compared to the CN market (33.9x).

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 300723's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: 300723 is overvalued based on its PB Ratio (4.8x) compared to the CN Pharmaceuticals industry average (2.7x).

Future Growth

How is Yipinhong PharmaceuticalLtd forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?


Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Yipinhong PharmaceuticalLtd has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has Yipinhong PharmaceuticalLtd performed over the past 5 years?


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 300723 has a high level of non-cash earnings.

Growing Profit Margin: 300723's current net profit margins (13.5%) are higher than last year (8.8%).

Past Earnings Growth Analysis

Earnings Trend: 300723's earnings have grown by 9.9% per year over the past 5 years.

Accelerating Growth: 300723's earnings growth over the past year (57.1%) exceeds its 5-year average (9.9% per year).

Earnings vs Industry: 300723 earnings growth over the past year (57.1%) exceeded the Pharmaceuticals industry 10.8%.

Return on Equity

High ROE: 300723's Return on Equity (15%) is considered low.

Financial Health

How is Yipinhong PharmaceuticalLtd's financial position?

Financial Position Analysis

Short Term Liabilities: 300723's short term assets (CN¥1.2B) exceed its short term liabilities (CN¥556.8M).

Long Term Liabilities: 300723's short term assets (CN¥1.2B) exceed its long term liabilities (CN¥93.3M).

Debt to Equity History and Analysis

Debt Level: 300723's debt to equity ratio (19.4%) is considered satisfactory.

Reducing Debt: 300723's debt to equity ratio has reduced from 176.6% to 19.4% over the past 5 years.

Debt Coverage: 300723's debt is well covered by operating cash flow (94.9%).

Interest Coverage: 300723 earns more interest than it pays, so coverage of interest payments is not a concern.

Balance Sheet


What is Yipinhong PharmaceuticalLtd current dividend yield, its reliability and sustainability?


Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: 300723's dividend (0.52%) is higher than the bottom 25% of dividend payers in the CN market (0.43%).

High Dividend: 300723's dividend (0.52%) is low compared to the top 25% of dividend payers in the CN market (1.81%).

Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, 300723 has been paying a dividend for less than 10 years.

Growing Dividend: 300723's dividend payments have increased, but the company has only paid a dividend for 3 years.

Current Payout to Shareholders

Dividend Coverage: With its low payout ratio (17.5%), 300723's dividend payments are well covered by earnings.

Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.

Next Steps


How experienced are the management team and are they aligned to shareholders interests?


Hanxiong Li (46 yo)

no data


Mr. Hanxiong Li serves as Chairman of the Board of Directors and General Manager at Yipinhong Pharmaceutical Co., Ltd. Mr. Li serves as Vice Chairman of Professional Committee of Pharmaceutical Clinical Re...


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Company Information

Yipinhong Pharmaceutical Co.,Ltd's company bio, employee growth, exchange listings and data sources

Key Information

  • Name: Yipinhong Pharmaceutical Co.,Ltd
  • Ticker: 300723
  • Exchange: SZSE
  • Founded: 2002
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CN¥7.531b
  • Shares outstanding: 157.78m
  • Website:

Number of Employees


  • Yipinhong Pharmaceutical Co.,Ltd
  • Star International Building
  • 17th Floor Tower
  • Guangzhou
  • Guangdong Province
  • 510623
  • China



Yipinhong Pharmaceutical Co.,Ltd, together with its subsidiaries, engages in the research and development, production, and sale of pharmaceutical products. It offers anti-infection, pediatric, cardiovascul...

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/11 09:17
End of Day Share Price2021/04/09 00:00
Annual Earnings2020/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.